SEARCH

SEARCH BY CITATION

References

  • 1
    Arend WP, Dayer J-M: Cytokines and cytokine inhibitors or antagonists in rheumatoid arthritis. Arthritis Rheum 33: 305315, 1990
  • 2
    Elliott MJ, Maini RN: New directions for biological therapy in rheumatoid arthritis. Int Arch Allergy Appl Immunol 104: 112125, 1994
  • 3
    Lacraz S, Isler P, Vey E, Welgus HG, Dayer J-M: Direct contact between T lymphocytes and monocytes is a major pathway for the induction of metalloproteinase expression. J Biol Chem 269: 2202722033, 1994
  • 4
    Hollander AP: Criteria for identifying mediators of tissue damage in human autoimmune diseases. Autoimmunity 9: 171176, 1991
  • 5
    Hollander AP, Atkins RM, Eastwood DM, Dieppe PA, Elson CJ: Human cartilage is degraded by rheumatoid arthritis synovial fluid but not by recombinant cytokines in vitro. Clin Exp Immunol 83: 5257, 1991
  • 6
    Brennan FM, Chantry D, Jackson A, Maini R, Feldmann M: Inhibitory effect of TNF α antibodies on synovial cell interleukin-1 production in rheumatoid arthritis. Lancet 2: 244247, 1989
  • 7
    Chandrasekhar S, Harvey AK, Hrubey PS, Bendele AM: Arthritis induced by interleukin-1 is dependent on the site and frequency of intraarticular injection. Clin Immunol Immunopathol 55: 382400, 1990
  • 8
    Staite ND, Richard KA, Aspar DG, Franz KA, Galinet LA, Dunn CJ: Induction of an acute erosive monarticular arthritis in mice by interleukin-1 and methylated bovine serum albumin. Arthritis Rheum 33: 253260, 1990
  • 9
    Van de Loo AAJ, Arntz OJ, van den Berg WB: Flare-up of experimental arthritis in mice with murine recombinant IL-1. Clin Exp Immunol 87: 196202, 1992
  • 10
    Hom JT, Cole H, Bendele AM: Interleukin-1 enhances the development of spontaneous arthritis in MRL/lpr mice. Clin Immunol Immunopathol 55: 109119, 1990
  • 11
    Hom JT, Cole H, Estridge T, Gliszczynski VL: Interleukin-1 enhances the development of type II collagen-induced arthritis only in susceptible and not in resistant mice. Clin Immunol Immunopathol 62: 5665, 1992
  • 12
    van de Loo AAJ, van den Berg WB: Effects of murine recombinant interleukin-1 on synovial joints in mice: measurement of patellar cartilage metabolism and joint inflammation. Ann Rheum Dis 49: 238245, 1990
  • 13
    Van Beuningen HM, Arntz OJ, van den Berg WB: In vivo effects of interleukin-1 on articular cartilage: prolongation of proteoglycan metabolic disturbances in old mice. Arthritis Rheum 34: 606615, 1991
  • 14
    O'Byrne EM, Blancuzzi V, Wilson DE, Wong M, Jeng AY: Elevated substance P and accelerated cartilage degradation in rabbit knees injected with interleukin-1 and tumor necrosis factor. Arthritis Rheum 33: 10231028, 1990
  • 15
    McDonnell J, Hoerrner LA, Lark MW, Harper C, Dey T, Lobner J, Eiermann G, Kazazis D, Singer II, Moore VL: Recombinant human interleukin-1 β-induced increase in levels of proteoglycans, stromelysin, and leukocytes in rabbit synovial fluid. Arthritis Rheum 35: 799805, 1992
  • 16
    Hasty KA, Reife RA, Kang AH, Stuart JM: The role of stromelysin in the cartilage destruction that accompanies inflammatory arthritis. Arthritis Rheum 33: 388397, 1990
  • 17
    Hutchinson NI, Lark MW, MacNaul KL, Harper C, Hoerrner LA, McDonnell J, Donatelli S, Moore V, Bayne EK: In vivo expression of stromelysin in synovium and cartilage of rabbits injected intraarticularly with interleukin-1β. Arthritis Rheum 35: 12271233, 1992
  • 18
    Case JP, Lafyatis R, Remmers EF, Kumkumian GK, Wilder RL: Transin/stromelysin expression in rheumatoid synovium. Am J Pathol 135: 10551064, 1989
  • 19
    McCachren SS, Haynes BF, Niedel JE: Localization of collagenase mRNA in rheumatoid arthritis synovium by in situ hybridization histochemistry. J Clin Immunol 10: 1927, 1990
  • 20
    Firestein GS, Paine MM: Stromelysin and tissue inhibitor of metalloproteinases gene expression in rheumatoid arthritis synovium. Am J Pathol 140: 13091314, 1992
  • 21
    Fons AF, van de Loo FA, Onno J, Arntz Otterness IG, van den Berg WB: Protection against cartilage proteoglycan synthesis inhibition by antiinterleukin-1 antibodies in experimental arthritis. J Rheumatol 19: 348356, 1992
  • 22
    van den Berg WB, Joostens LAB, Helsen M, van de Loo FA: Amelioration of established murine collagen-induced arthritis with anti-IL-1 treatment. Clin Exp Immunol 95: 237243, 1994
  • 23
    Yodlowski ML, Hubbard JR, Kispert J, Keller K, Sledge CB, Steinberg JJ: Antibody to interleukin-1 inhibits the cartilage degradative and thymocyte proliferative actions of rheumatoid synovial culture medium. J Rheumatol 17: 16001607, 1990
  • 24
    Arend WP: Interleukin-1 receptor antagonist. Adv Immunol 54: 167227, 1993
  • 25
    Arend WP, Welgus HG, Thompson RC, Eisenberg SP: Biological properties of recombinant human monocyte-derived interleukin-1 receptor antagonist. J Clin Invest 85: 16941697, 1990
  • 26
    Seckinger P, Kaufmann M-T, Dayer J-M: An interleukin-1 inhibitor affects both cell-associated interleukin-1-induced T cell proliferation and PGE2/collagenase production by human dermal fibroblasts and synovial cells. Immunobiology 180: 316327, 1990
  • 27
    Seckinger P, Klein-Nulend J, Alander C, Thompson RC, Dayer J-M, Raisz LG: Natural and recombinant human IL-1 receptor antagonists block the effects of IL-1 on bone resorption and prostaglandin production. J Immunol 145: 41814184, 1990
  • 28
    Seckinger P, Yaron I, Meyer FA, Yaron M, Dayer J-M: Modulation of the effects of interleukin-1 on glycosaminoglycan synthesis by the urine-derived interleukin-1 inhibitor, but not by interleukin-6. Arthritis Rheum 33: 18071814, 1990
  • 29
    Smith RJ, Chin JE, Sam LM, Justen JM: Biologic effects of an interleukin-1 receptor antagonist protein on interleukin-1-stimulated cartilage erosion and chondrocyte responsiveness. Arthritis Rheum 34: 7883, 1991
  • 30
    Smith RJ, Justen JM, Ulrich RG, Lund JE, Sam LM: Induction of neutral proteinase and prostanoid production in bovine nasal chondrocytes by interleukin-1 and tumor necrosis factor α: modulation of these cellular responses by interleukin-6 and platelet-derived growth factor. Clin Immunol Immunopathol 64: 135144, 1992
  • 31
    Schwab JH, Anderle SK, Brown RR, Dalldorf FG, Thompson RC: Pro- and anti-inflammatory roles of interleukin-1 in recurrence of bacterial cell wall-induced arthritis in rats. Infect Immun 59: 44364442, 1991
  • 32
    Matsukawa A, Ohkawara S, Maeda T, Takagi K, Yoshinaga M: Production of IL-1 and IL-1 receptor antagonist and the pathological significance in lipopolysaccharide-induced arthritis in rabbits. Clin Exp Immunol 93: 206211, 1993
  • 33
    Wooley PH, Whalen JD, Chapman DL, Berger AE, Richard KA, Aspar DG, Staite ND: The effect of an interleukin-1 receptor antagonist protein on type II collagen-induced arthritis and antigen-induced arthritis in mice. Arthritis Rheum 36: 13051314, 1993
  • 34
    Henderson B, Thompson RC, Hardingham T, Lewthwaite J: Inhibition of interleukin-1-induced synovitis and articular cartilage proteoglycan loss in the rabbit knee by recombinant human interleukin-1 receptor antagonist. Cytokine 3: 246249, 1991
  • 35
    Lewthwaite J, Blake SM, Hardingham TE, Warden PJ, Henderson B: The effect of recombinant human interleukin-1 receptor antagonist on the induction phase of antigen induced arthritis in the rabbit. J Rheumatol 21: 467472, 1994
  • 36
    Allen JB, Wong HL, Costa GL, Bienkowski MJ, Wahl SM: Suppression of monocyte function and differential regulation of IL-1 and IL-lra by IL-4 contribute to resolution of experimental arthritis. J Immunol 151: 43444351, 1993
  • 37
    Barkley DEH, Feldmann M, Maini RN: Cells with dendritic morphology and bright interleukin-1 α staining circulate in the blood of patients with rheumatoid arthritis. Clin Exp Immunol 80: 2531, 1990
  • 38
    Goto M, Fujisawa M, Yamada A, Okabe T, Takaku F, Sasano M, Nishioka K: Spontaneous release of angiotensin converting enzyme and interleukin-1β from peripheral blood monocytes from patients with rheumatoid arthritis under a serum free condition. Ann Rheum Dis 49: 172176, 1990
  • 39
    Zangerle PF, De Groote D, Lopez M, Meuleman RJ, Vrindts Y, Fauchet F, Dehart I, Jadoul M, Radoux D, Franchimont P: Direct stimulation of cytokines (IL-1β, TNF-α, IL-6, IFN γ and GM-CSF) in whole blood. II. Application to rheumatoid arthritis and osteoarthritis. Cytokine 4: 568575, 1992
  • 40
    Ruschen S, Stellberg W, Warnatz H: Kinetics of cytokine secretion by mononuclear cells of the blood from rheumatoid arthritis patients are different from those of healthy controls. Clin Exp Immunol 89: 3237, 1992
  • 41
    Dularay B, Westacott CI, Elson CJ: IL-1 secreting cell assay and its application to cells from patients with rheumatoid arthritis. Br J Rheumatol 31: 1924, 1992
  • 42
    Holt I, Cooper RG, Denton J, Meager A, Hopkins SJ: Cytokine inter-relationships and their association with disease activity in arthritis. Br J Rheumatol 31: 725733, 1992
  • 43
    Kahle P, Saal JG, Schaudt K, Zacher J, Fritz P, Pawelee G: Determination of cytokines in synovial fluids: correlation with diagnosis and histomorphological characteristics of synovial tissue. Ann Rheum Dis 51: 731734, 1992
  • 44
    Malyak M, Swaney RE, Arend WP: Levels of synovial fluid interleukin-1 receptor antagonist in rheumatoid arthritis and other arthropathies: potential contribution from synovial fluid neutrophils. Arthritis Rheum 36: 781789, 1993
  • 45
    Miller LC, Lynch EA, Isa S, Logan JW, Dinarello CA, Steere AC: Balance of synovial fluid IL-1β and IL-1 receptor antagonist and recovery from Lyme disease. Lancet 341: 146148, 1993
  • 46
    Firestein GS, Alvaro-Garcia JM, Maki R: Quantitative analysis of cytokine gene expression in rheumatoid arthritis. J Immunol 144: 33473353, 1990
  • 47
    Chu CQ, Field M, Allard S, Abney E, Feldmann M, Maini RN: Detection of cytokines at the cartilage/pannus junction in patients with rheumatoid arthritis: implications for the role of cytokines in cartilage destruction and repair. Br J Rheumatol 31: 653661, 1992
  • 48
    Wood NC, Dickens E, Symons JA, Duff GW: In situ hybridization of interleukin-1 in CD14-positive cells in rheumatoid arthritis. Clin Immunol Immunopathol 62: 295300, 1992
  • 49
    Yanni G, Whelan A, Feighery C, Quinlan W, Symons J, Duff G, Bresnihan B: Contrasting levels of in vitro cytokine production by rheumatoid synovial tissues demonstrating different patterns of mononuclear cell infiltration. Clin Exp Immunol 93: 387395, 1993
  • 50
    Farahat MN, Yanni G, Poston R, Panayi GS: Cytokine expression in synovial membranes of patients with rheumatoid arthritis and osteoarthritis. Ann Rheum Dis 52: 870875, 1993
  • 51
    Firestein GS, Berger AE, Tracey DE, Chosay JG, Chapman DL, Paine MM, Yu C, Zvaifler NJ: IL-1 receptor antagonist protein production and gene expression in rheumatoid arthritis and osteoarthritis synovium. J Immunol 149: 10541062, 1992
  • 52
    Koch AE, Kunkel SL, Chensue SW, Haines GK, Strieter RM: Expression of interleukin-1 and interleukin-1 receptor antagonist by human rheumatoid synovial tissue macrophages. Clin Immunol Immunopathol 65: 2329, 1992
  • 53
    Deleuran BW, Chu CQ, Field M, Brennan FM, Katsikis P, Feldmann M, Maini RN: Localization of interleukin-1 α, type 1 interleukin-1 receptor and interleukin-1 receptor antagonist in the synovial membrane and cartilage/pannus junction in rheumatoid arthritis. Br J Rheumatol 31: 801809, 1992
  • 54
    Firestein GS, Boyle D, Yu C, Paine MM, Whisenand TD, Zvaifler NJ, Arend WP: Synovial interleukin-1 receptor antagonist and interleukin-1 balance in rheumatoid arthritis. Arthritis Rheum 37: 644652, 1994
  • 55
    Danis VA, Kulesz AJ, Nelson DS, Brooks PM: The effect of gold sodium thiomalate and auranofin on lipopolysaccharide-induced interleukin-1 production by blood monocytes in vitro: variation in healthy subjects and patients with arthritis. Clin Exp Immunol 79: 335340, 1990
  • 56
    Chang D-M, Weinblatt ME, Schur PH: The effects of methotrexate on interleukin-1 in patients with rheumatoid arthritis. J Rheumatol 19: 16781682, 1992
  • 57
    Meyer FA, Yaron I, Mashiah V, Yaron M: Methotrexate inhibits proliferation but not interleukin-1-stimulated secretory activities of cultured human synovial fibroblasts. J Rheumatol 20: 238242, 1993
  • 58
    Thomas R, Carroll GJ: Reduction of leukocyte and interleukin-1 β concentrations in the synovial fluid of rheumatoid arthritis patients treated with methotrexate. Arthritis Rheum 36: 12441252, 1993
  • 59
    Thornberry NA, Peterson EP, Zhao JJ, Howard AD, Griffin PR, Chapman KT: Inactivation of interleukin-1β converting enzyme by peptide (acyloxy)methyl ketones. Biochemistry 33: 39343940, 1994
  • 60
    Symons JA, Eastgate JA, Duff GW: A soluble binding protein specific for interleukin-1β is produced by activated mononuclear cells. Cytokine 2: 190198, 1990
  • 61
    Symons JA, Eastgate JA, Duff GW: Purification and characterization of a novel soluble receptor for interleukin-1. J Exp Med 174: 12511254, 1991
  • 62
    Dreylow B, Capezio J, Lovis R, Jacobs C, Landay A, Pope RM: Phase I study of recombinant human interleukin-1 receptor administered intra-articularly in active rheumatoid arthritis (abstract). Arthritis Rheum 36 (Suppl 9): S39, 1993
  • 63
    Lebsack ME, Paul CC, Bloedow DC, Burch FX, Sack MA, Chase W, Catalano MA: Subcutaneous IL-1 receptor antagonist in patients with rheumatoid arthritis (abstract). Arthritis Rheum 34 (Suppl 9): S45, 1991
  • 64
    Lebsack ME, Paul CC, Martindale JJ, Catalano MA: A dose-and regimen-ranging study of IL-1 receptor antagonist in patients with rheumatoid arthritis (abstract). Arthritis Rheum 36 (Suppl 9): S39, 1993
  • 65
    Evans C, Robbins PD: Prospects for treating arthritis by gene therapy. J Rheumatol 21: 779782, 1994
  • 66
    Roessler FJ, Allen ED, Wilson JM, Hartman JW, Davidson BL: Adenoviral-mediated gene transfer to rabbit synovium in vivo. J Clin Invest 92: 10851092, 1993
  • 67
    Hartman JW, Davidson BL, Roessler FJ: Genetic modification of synoviocytes in vivo using recombinant adenoviral vectors (abstract). Arthritis Rheum 36 (Suppl 9): S64, 1993
  • 68
    Bandara G, Mueller GM, Galea-Lauri J, Tindal MH, Georgescu HI, Suchaneek MK, Hung GHL, Glorioso JC, Robbins PD, Evans CH: Intraarticular expression of biologically active interleukin-1-receptor-antagonist protein by ex vivo gene transfer. Proc Natl Acad Sci U S A 90: 1076410768, 1993
  • 69
    Brennan FM, Maini RN, Feldmann M: TNFα-a pivotal role in rheumatoid arthritis. Br J Rheumatol 31: 293298, 1992
  • 70
    Dayer J-M, Fenner H: The role of cytokines and their inhibitors in arthritis. Ballieres Clin Rheumatol 6: 485516, 1992
  • 71
    Haworth C, Brennan FM, Chantry D, Turner M, Maini RN, Feldmann M: Expression of granulocyte-macrophage colony-stimulating factor in rheumatoid arthritis: regulation by tumor necrosis factor-α. Eur J Immunol 21: 25752579, 1991
  • 72
    Campbell IK, Piccoli DS, Roberts MJ, Muirden KD, Hamilton JA: Effects of tumor necrosis factor α and β on resorption of human articular cartilage and production of plasminogen activator by human articular chondrocytes. Arthritis Rheum 33: 542552, 1990
  • 73
    Zarco P, Maestre C, Herrero-Beaumont G, Gonzalez E, Garcia-Hoyo R, Navarro FJ, Braquet P, Egido J: Involvement of platelet-activating factor and tumor necrosis factor in the pathogenesis of joint inflammation in rabbits. Clin Exp Immunol 88: 318323, 1992
  • 74
    Keffer J, Probert L, Cazlaris H, Georgopoulos S, Kaslaris E, Kioussis D, Kollias G: Transgenic mice expressing human tumor necrosis factor: a predictive genetic model of arthritis. EMBO J 10: 40254031, 1991
  • 75
    Brahn E, Peacock DJ, Banquerigo ML, Liu DY: Effects of tumor necrosis alpha (TNF-α) on collagen arthritis. Lymphokine Cytokine Res 11: 253256, 1992
  • 76
    Cooper WO, Fava RA, Gates CA, Cremer MA, Townes AS: Acceleration of onset of collagen-induced arthritis by intraarticular injection of tumour necrosis factor or transforming growth factor-beta. Clin Exp Immunol 898: 244250, 1992
  • 77
    Thorbecke G, Shah R, Leu CH, Kuruvilla AP, Hardison AM, Palladino MA: Involvement of endogenous tumor necrosis factor α and transforming growth factor β during induction of collagen type II arthritis in mice. Proc Natl Acad Sci U S A 89: 73757379, 1992
  • 78
    Piquet PF, Grau GE, Vesin C, Loetscher H, Gentz R, Lesslauer W: Evolution of collagen arthritis in mice is arrested by treatment with anti-tumour necrosis factor (TNF) antibody or a recombinant soluble TNF receptor. Immunology 77: 510514, 1992
  • 79
    Williams RO, Feldmann M, Maini RN: Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis. Proc Natl Acad Sci U S A 89: 97849788, 1992
  • 80
    Williams RO, Mason LJ, Feldmann M, Maini RN: Synergy between anti-CD4 and anti-tumor necrosis factor in the amelioration of established collagen-induced arthritis. Proc Natl Acad Sci U S A 91: 27622766, 1994
  • 81
    Wooley PH, Dutcher J, Widmer MB, Gillis S: Influence of a recombinant human soluble tumor necrosis factor receptor Fc fusion protein on type II collagen-induced arthritis in mice. J Immunol 151: 66026607, 1993
  • 82
    Tetta C, Camussi G, Modena V, Di Vittorio C, Baglioni C: Tumour necrosis factor in serum and synovial fluid of patients with active and severe rheumatoid arthritis. Ann Rheum Dis 49: 665667, 1990
  • 83
    Chu CQ, Field M, Feldmann M, Maini RN: Localization of tumor necrosis factor α in synovial tissues and at the cartilagepannus junction in patients with rheumatoid arthritis. Arthritis Rheum 34: 11251132, 1991
  • 84
    Deleuran BW, Chu C-Q, Field M, Brennan FM, Mitchell T, Feldmann M, Maini RN: Localization of tumor necrosis factor receptors in the synovial tissue and cartilage-pannus junction in patients with rheumatoid arthritis: implications for local actions of tumor necrosis factor α. Arthritis Rheum 35: 11701178, 1992
  • 85
    Brennan FM, Gibbons DL, Mitchell T, Cope AP, Maini RN, Feldmann M: Enhanced expression of tumor necrosis factor receptor mRNA and protein in mononuclear cells isolated from rheumatoid arthritis synovial joints. Eur J Immunol 22: 19071912, 1992
  • 86
    Sampaio EP, Sarno EN, Galilly R, Cohn ZA, Kaplan G: Thalidomide selectively inhibits tumor necrosis factor α production by stimulated human monocytes. J Exp Med 173: 699703, 1991
  • 87
    Van Leenan D, van der Poll T, Levi M, ten Cate H, van Deventer SJH, Hack CE, Aarden LA, ten Cate JW: Pentoxifylline attenuates neutrophil activation in experimental endotoxemia in chimpanzees. J Immunol 151: 23182325, 1993
  • 88
    Parmely MJ, Zhou W-W, Edwards CK III, Borcherding DR, Silverstein R, Morrison DC: Adenosine and a related carbocyclic nucleoside analogue selectively inhibit tumor necrosis factor-α production and protect mice against endotoxin challenge. J Immunol 151: 389396, 1993
  • 89
    Barrera P, Boerbooms AMT, Janssen EM, Sauerwein RW, Gallati H, Mulder J, de Boo T, Demacker PNM, van de Putte LBA, van der Meer JWM: Circulating soluble tumor necrosis factor receptors, interleukin-2 receptors, tumor necrosis factor α, and interleukin-6 levels in rheumatoid arthritis: longitudinal evaluation during methotrexate and azathioprine therapy. Arthritis Rheum 36: 10701079, 1993
  • 90
    Cope AP, Aderka D, Doherty M, Engelmann H, Gibbons D, Jones AC, Brennan FM, Maini RN, Wallach D, Feldmann M: Increased levels of soluble tumor necrosis factor receptors in the sera and synovial fluid of patients with rheumatic diseases. Arthritis Rheum 35: 11601169, 1992
  • 91
    Chikanza IC, Roux-Lombard P, Dayer J-M, Panayi GS: Tumour necrosis factor soluble receptors behave as acute phase reactants following surgery in patients with rheumatoid arthritis, chronic osteomyelitis and osteoarthritis. Clin Exp Immunol 92: 1922, 1993
  • 92
    Roux-Lombard P, Punzi L, Hasler F, Bas S, Todesco S, Gallati H, Guerne P-A, Dayer J-M: Soluble tumor necrosis factor receptors in human inflammatory synovial fluids. Arthritis Rheum 36: 485489, 1993
  • 93
    Aderka D, Engelmann H, Maor Y, Brakebusch C, Wallach D: Stabilization of the bioactivity of tumor necrosis factor by its soluble receptors. J Exp Med 175: 323329, 1992
  • 94
    Moreland LW, Margolies GR, Heck LW, Saway PA, Jacobs C, Beck C, Blosch C, Koopman WJ: Soluble tumor necrosis factor receptor: results of a phase I dose-escalation study in patients with rheumatoid arthritis (abstract). Arthritis Rheum 37 (Suppl 6): R27, 1994
  • 95
    Elliott MJ, Maini RN, Feldmann M, Long-Fox A, Charles P, Katsikis P, Brennan FM, Walker J, Bijl H, Ghrayeb J, Woody JN: Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor α. Arthritis Rheum 36: 16811690, 1993
  • 96
    Elliott MJ, Maini RN, Feldmann M, Kalden JR, Antoni C, Smolen J, Leeb B, Breedveld EC, Macfarlane JD, Bijl JA, Woody JN: TNF α blockade in rheumatoid arthritis: results of a multicenter placebo-controlled, double-blind trial of chimeric anti-TNF α monoclonal antibody (cA2) in refractory disease (abstract). Arthritis Rheum 37 (Suppl 9): S283, 1994
  • 97
    Rankin ECC, Choy EHS, Kassimos D, Sopwith M, Kingsley G, Isenberg DA, Panayi GS: A double blind, placebocontrolled, ascending dose trial of the recombinant humanised anti-TNFα antibody CDP571 in patients with rheumatoid arthritis: a preliminary report (abstract). Arthritis Rheum 37 (Suppl 9): S295, 1994
  • 98
    Cope AP, Londei M, Chu NR, Cohen SBA, Elliott MJ, Brennan FM, Maini RN, Feldmann M: Chronic exposure to tumor necrosis factor (TNF) in vitro impairs the activation of T cells through the T cell receptor/CD3 complex: reversal in vivo by anti-TNF antibodies in patients with rheumatoid arthritis. J Clin Invest 94: 749760, 1994
  • 99
    Campion GV: The prospect for cytokine based therapeutic strategies in rheumatoid arthritis. Ann Rheum Dis 53: 485487, 1994
  • 100
    Van den Berg WS, Joosten LAB, Helsen MA, van Lent PLEM, van de Loo FAJ: Cytokine profile dependent on the type of arthritis: dominant role of IL-1 in cartilage destruction (abtract). Arthritis Rheum 37 (Suppl 9): S193, 1994
  • 101
    Russell D, Tucker K, Kohno H, Thompson RC, Schwab J: Inhibition of tumor necrosis factor is effective alone or in combination with inhibition of interleukin-1 in reducing joint swelling in rodent bacterial cell wall-induced arthritis (abstract). Arthritis Rheum 37 (Suppl 9): S279, 1994